Subscribe for the Newsletter

Mobile Navigation

Bringing Regulatory Expectations for Real-World Evidence Into Alignment

Bringing Regulatory Expectations for Real-World Evidence Into Alignment

Nov 16, 2026PAO-11-26-PA-08

Key Takeaways

  • Real-world evidence (RWE) is increasingly used in drug discovery, clinical trial design, and marketing approval submissions.

  • Regulatory bodies around the world recognize the value of RWE, but individual authorities have taken varying approaches to the governance of its use, including different expectations for data quality and application methodologies, study designs, endpoint definitions, and submission standards.

  • There is also a lack of consistent definitions for RWE and real-world data (RWD), which in some cases are used interchangeably.

  • Regulatory harmonization would support the development of adaptive, collaborative frameworks, promote more consistent risk-benefit assessments, and streamline submissions and reviews for drug candidates whose applications include RWE.

  • The International Council for Harmonisation (ICH) is taking steps to develop harmonized guidance on RWE, beginning with a reflection paper endorsed in June 2024. A final concept paper endorsed in November 2025 describes the remit of the Expert Working Group. The February 2026 work plan targets September 2027 for draft guideline sign-off and the start of public consultation.

  • Despite notable differences in operational expectations regarding RWE use in drug development, the list of applications continues to grow, and harmonization of regulations should accelerate its adoption, improve the quality of data employed, and facilitate regulatory decision-making.

Consensus on Value, but Different Ways of Using RWE

Real-world evidence (RWE), or clinical evidence about a medical product’s use and potential benefits or risks derived from analysis of real-world data (RWD), has been increasingly used in a variety of applications from drug discovery to clinical trial design to marketing approval submissions. RWD are routinely collected data on patient health or healthcare delivery from sources such as health records, claims, registries, and digital health technologies. Regulatory bodies around the world recognize the value of RWE, but individual authorities have taken varying approaches to the governance of its use, including different expectations for data quality and application methodologies, study designs, endpoint definitions, and submission standards.1,2 There is also a lack of consistent definitions for RWE and RWD, which in some cases are used interchangeably.2

Many Potential Benefits of RWE Harmonization

Increasing use of RWE has driven the need for more “adaptive, collaborative frameworks” for pharmaceutical regulation.3 Regulatory harmonization would enable the development of such frameworks, allow for more consistent risk-benefit assessments, and enable streamlining of application submissions and the review process while still ensuring safety.

More specifically, harmonized RWE standards would reduce the need for duplicated work across submissions to different authorities, enable faster decision-making, allow high-quality RWE generated in various regions to be used to support global studies, create better opportunities for equal patient access, and help increase the efficiency of healthcare data use.1 Aligning expectations across all stakeholders, including regulators, drug developers, contract service providers, academia, patients, advocacy groups, the World Health Organization (WHO), and other groups that use RWE, could accelerate decision-making, facilitate the development of novel medicines, and ensure the safe and effective use of existing drug products.4

Several Key Issues

Harmonization of regulations on the use of RWE in drug discovery and development would help address several key issues currently facing the sector due to the lack of standardization of guidelines.2,4 First, harmonized guidelines would establish internationally recognized definitions for RWE and RWD that would replace the similar but varying definitions in use by the U.S. Food and Drug Administration (FDA), European Medicines Agency, and other authorities. A single set of definitions would allow for better data and evidence tracking and reduce the risk of confusion between users of RWE/RWD and different regulatory bodies about what is considered RWE and RWD and how they can be used.

Second, harmonized expectations for data quality and traceability would lead to an overall improvement in these attributes for RWD used for drug development. Standardization would establish the means for clearly delineating/describing data sources and demonstrating their validity and reliability with respect to patient health attributes and received care/treatment.

Third, standards regarding statistical analysis methods used with RWE would help minimize concerns about selection bias, missing data, and confounding that currently exist due to the wide variety of methods being applied in accordance with varying regulations.

Fourth, establishment of standard forms covering RWE aspects of drug approval applications and templates for reviewing submissions, as well as the generation of collaborative models for joint assessments, would simplify and accelerate multi-region submissions.

Initial Steps by ICH

The International Coalition of Medicines Regulatory Authorities (ICMRA) is a “voluntary, executive-level, strategic coordinating, advocacy and leadership entity of regulatory authorities that work together to” address global regulatory and safety challenges in human medicine, identify areas of common interest and with potential synergies for varying regulatory authorities and provide guidance on potential actions, and where possible highlight existing initiatives and resources that can be used.5

In 2022, ICMRA committed to fostering international collaboration on RWE.6 The International Council for Harmonisation (ICH) responded with a reflection paper led by the European Commission (EC), Health Canada, and the FDA “outlining a strategy towards harmonization.”4 This strategy, which was endorsed by the ICH Assembly, included a step-wise approach starting with issuance of an ICH guideline focusing on RWD and RWE terminologies, metadata, and assessment principles, building on ICH M147, which focuses on the use of RWD for safety assessment. In November 2025, the ICH Management Committee endorsed Final Concept Paper E23: Considerations for the Use of Real-World Evidence (RWE) to Inform Regulatory Decision Making with a focus on Effectiveness of Medicines.2

The 2024 Reflection Paper not only proposed an approach for addressing the challenges posed by a lack of global standardization in regulatory expectations for RWE, but included a plan for integration of RWE into regulatory submissions and a mechanism for accelerating regulatory reviews.4 The strategy considered issues such as the diversity of RWE sources, types, and formats and the varying levels of data quality and validity and approaches to governance. The goals were to “engage ICH on convergence of terminology for RWD and RWE, on the format for protocols and reports of study results submitted to regulatory agencies throughout the lifecycle of medicinal products, and on promoting registration of protocols and reports” and “inform the assessment of RWD and RWE for regulatory purposes,” ultimately leading to higher-quality RWE used to support the assessment of the benefits and risks of medicines in development.

The 2025 Concept Paper outlined expectations for a new ICH guideline for the use of RWE and RWD and its deliverables. The latter include harmonized definitions for both, a core list of metadata, and general principles for RWD/RWE assessment when used to inform regulatory assessments of the effectiveness of medicines.2 The Expert Working Group includes experts from regulatory agencies, industry, and observer organizations, with expertise in pharmacoepidemiology, biostatistics, RWD curation and standards, and RWE methodologies. The February 2026 work plan targets September 2027 for draft guideline sign-off and the start of public consultation.8

Another important component of ICH’s multi-step strategy for harmonizing regulatory expectations for RWE is interfacing with other RWE-related regulatory initiatives taking place around the world, including those in Europe, the United States, and Canada.4

ISPE Active Too

Separate from the ICH moves toward harmonizing regulatory expectations for RWE, the International Society for Pharmacoepidemiology (ISPE) and The Professional Society for Health Economics and Outcomes Research (ISPOR) developed the HARmonized Protocol Template to Enhance Reproducibility (HARPER).9,10 HARPER provides a set of core recommendations to enable researchers to develop transparent and reproducible RWE study protocols. It was created by a joint task force including members from both organizations and representatives of various international stakeholder groups (regulatory agencies, health technology assessment (HTA) organizations, industry, and academia) to help researchers document the reasons for selected study parameters, enable reviewers to readily assess the potential for bias in those choices, and increase reproducibility.

Encouraging Progress

In a recent study of RWE guidance issued by twelve major regulatory and HTA agencies comparing approaches to data quality, statistical methods, registry governance, and transparency, it was found that while there was good agreement regarding “high-level principles,” operational expectations differed notably and lacked harmonization (defined as “alignment across these domains sufficient to enable consistent planning, analysis and interpretation of RWE across jurisdictions”). The author concluded that “RWE fragmentation reflects both legitimate functional differences and avoidable operational misalignment.”11

Despite these results, there has been progress on the alignment of regulations regarding the use of RWE and how it fits into regulatory decision-making.1 RWE is finding use in submissions for marketing authorizations for novel drugs, particularly advanced therapy medicinal products and drugs for rare diseases. RWE collected post-approval is also supporting conditional marketing authorizations, label updates and indication expansions, risk assessments and risk-benefit analyses, and health technology assessments.

References

1. Singh, Aditya. “Harmonizing Global RWE Standards Across Regions.” RWE Navigator. 7 May 2026.

2. “Final Concept Paper E23: Considerations for the Use of Real-World Evidence (RWE) to Inform Regulatory Decision Making with a focus on Effectiveness of Medicines.” International Council for Harmonisation (ICH). 22 Oct. 2025. Endorsed 12 Nov. 2025.

3. Chisholm, Orin, Elaine Y L Blair, and Christine Y Lu. “Regulatory harmonization: Evolution, globalization and future directions.” British Journal of Clinical Pharmacology. 28 Jul. 2026. e70716.

4. “ICH reflection paper on pursuing opportunities for harmonisation in using real-world data to generate real-world evidence, with a focus on effectiveness of medicines.” International Council for Harmonisation (ICH). 3 Jul. 2024.

5. “Home.” International Coalition of Medicines Regulatory Authorities (ICMRA). Accessed 12 Nov. 2026.

6. “ICMRA statement on international collaboration to enable real-world evidence (RWE) for regulatory decision-making.” International Coalition of Medicines Regulatory Authorities (ICMRA). Jul. 2022.

7. “ICH M14 Guideline: General Principles on Planning, Designing, Analysing, and Reporting of Non-interventional Studies That Utilise Real-World Data for Safety Assessment of Medicines.” International Council for Harmonisation (ICH). 4 Sep. 2025.

8. “ICH E23 EWG Work Plan.” International Council for Harmonisation (ICH). 12 Feb. 2026.

9. “Global Expert Panel Publishes New Guidance on Designing and Conducting Real-World Evidence Studies.” ISPOR. 11 Oct. 2022.

10. Wang, Shirley V, et al. “HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force.” Value in Health. 25: 1663–1672 (2022).

11. Sagkriotis, Alexandros. “Advancing real-world evidence harmonization: lessons from the UK, EMA and global policy frameworks.” Journal of Comparative Effectiveness Research. 15: e250183 (2026).